On-Demand CME Videos
Advances in Diagnostic and Prognostic Testing in Cutaneous Melanoma: Online CME Activity
To find out the correct answer, click "Start Activity."
Why is it important to improve patient selection for SLNB surgical procedure? Select the best answer below.
a. Majority of patients that undergo the procedure are negative
b. Reduce exposure to unnecessary anesthesia risks and surgical complications
c. Reduce healthcare costs
d. SLNB carries a false negative rate of almost 18%
e. All of the above
This activity is supported by an educational grant from Castle Biosciences.
In order to ensure educational material is relevant, educational materials will expire after a certain time period. This course will be available for the following dates:
December 2, 2022
December 2, 2023
At the completion of this activity, participants should be better able to:
Summarize the epidemiology of malignant melanoma
Describe the current challenges of accurately diagnosing and predicting the behavior of malignant melanoma
Evaluate current and emerging data surrounding outcomes using these technologies
Outline current guideline recommendations regarding the implementation of these GEP technologies
Aaron Farberg, MD
Baylor Scott & White Health System
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the Institute for Continuing Healthcare Education and CMEsquared. The Institute is accredited by the ACCME to provide continuing medical education for physicians.
Credit Designation Statement
The Institute for Continuing Healthcare Education designates this live and enduring activity for a maximum of 1 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Disclosures & Disclaimers
Disclosures are as follows:
Speakers’ Bureau or Honoraria: Novartis, Sanofi Regeneron, SUN Pharma, Galderma, Castle Biosciences, Janssen, Ortho Dermatologics, Pfizer
The Institute discloses that all relevant conflicts have been satisfactorily mitigated.